Latest / Cyrona Cell Podcast: Stem Cell Therapy in Malaysia / Crohn’s Perianal Fistulas: What Phase 3 MSC Trials Show
Transcript
- 0:00SPEAKER_00: Welcome to the Sarona Cell Podcast.
- 0:02SPEAKER_00: Today, imagine you're looking at a medical treatment that cleared, well, pretty much every conceivable hurdle in modern science.
- 0:09SPEAKER_01: Yeah, the absolute gold standard.
- 0:10SPEAKER_00: You run the trials, you prove to regulators across the globe that it works, you get the gold stamp of approval, and it hits the market as this medical breakthrough.
- 0:19SPEAKER_00: And then a decade later, it loses that approval and gets pulled.
- 0:23SPEAKER_01: Which usually means something went terribly wrong.
- 0:25SPEAKER_00: Aaron Powell But here's the wild twist.
- 0:27SPEAKER_00: The treatment didn't actually get worse.
- 0:29SPEAKER_00: The drug itself performed almost exactly the same.
- 0:32SPEAKER_00: Everything else around it simply got better.
- 0:34SPEAKER_00: So today's mission is unpacking an article from the Cyrona Cell blog detailing the stem cell trial results for perienal fistulas.
- 0:42SPEAKER_00: We are going to explore how a massive follow-up study completely rewrote the fate of a drug that was once considered a pioneer.
- 0:50SPEAKER_01: This deep dive is honestly the perfect case study in how medical evidence behaves in the real world.
- 0:55SPEAKER_01: We all tend to view clinical trials and FDA or EMA approvals as a finish line.
- 1:01SPEAKER_01: You know, you get the approval and the book is closed.
- 1:03SPEAKER_00: You pop the champagne and that's it.
- 1:05SPEAKER_00: But science is not a static environment.
- 1:07SPEAKER_00: It is this constantly shifting landscape.
- 1:10SPEAKER_00: The effectiveness of any medical treatment is only ever measured relative to the environment it exists in.
- 1:16SPEAKER_00: So if the baseline of care shifts, suddenly a breakthrough can look entirely average, even if the drug itself is still doing its exact job.
- 1:25SPEAKER_01: Okay, let's unpack this.
- 1:26SPEAKER_01: Because to understand why this story is so fascinating, you really need to understand the absolute nightmare that researchers were trying to solve in the first place.
- 1:33SPEAKER_01: We're talking about complex Crohn's perienal fistulas.
- 1:37SPEAKER_00: Which is incredibly difficult to manage.
- 1:39SPEAKER_01: For anyone lucky enough not to know what that means, a fistula is essentially an abnormal tunnel connecting two spaces in the body that should absolutely not be connected.
- 1:48SPEAKER_01: It's like a rogue pathway.
- 1:50SPEAKER_01: And when we look at the clinical data today, they use something called the St.
- 1:53SPEAKER_01: James's University Hospital MRI grading system to classify just how bad these tunnels were.
- 2:00SPEAKER_00: And that grading is crucial because not all fistulas are created equal.
- 2:04SPEAKER_00: Right.
- 2:04SPEAKER_00: And the patients in these trials were largely dealing with a grade three transphincteric fistula.
- 2:10SPEAKER_00: So break that down for us.
- 2:12SPEAKER_00: What does that actually look like anatomically?
- 2:14SPEAKER_01: Anatomically, it is a surgeon's worst-case scenario.
- 2:17SPEAKER_01: A grade three transphinceric fistula means the tunnel starts inside the anal canal and then it literally bores its way through both the internal and the external sincter muscles before finally breaking out at the surface of the skin.
- 2:30SPEAKER_00: So it's passing straight through the crucial muscular architecture that controls a person's bowel movements.
- 2:35SPEAKER_01: Yes.
- 2:36SPEAKER_00: Which means you can't just go in with a scalpel and cut the tunnel out.
- 2:39SPEAKER_01: You cannot.
- 2:40SPEAKER_01: If a surgeon simply cuts that tract away, they risk slicing through those sincter muscles.
- 2:45SPEAKER_01: And that can leave the patient with permanent debilitating incontinence.
- 2:48SPEAKER_00: So you are trapped between a rock and a hard place.
- 2:51SPEAKER_01: You really are.
- 2:52SPEAKER_01: Patients with these complex fistulas face a terrible cycle.
- 2:55SPEAKER_01: The tunnel constantly fills with fluid and bacteria, which leads to massive painful abscesses.
- 3:01SPEAKER_00: And they just keep coming back, right?
- 3:02SPEAKER_01: They undergo repeated surgeries to drain these infections, often with very little long-term success.
- 3:08SPEAKER_01: And these tracks essentially never close on their own.
- 3:10SPEAKER_01: The body is in a state of chronic inflammation, actively preventing the tissue from healing.
- 3:15SPEAKER_00: Which is why colorectal surgeons have to be involved on day one using incredibly detailed MRI monitoring to map every single millimeter of the tract before they even think about formulating a treatment plan.
- 3:27SPEAKER_01: Because if you go in blind, the consequences are catastrophic.
- 3:30SPEAKER_00: So you have this impossible anatomical puzzle.
- 3:33SPEAKER_00: The stakes are incredibly high for the patient.
- 3:36SPEAKER_00: But this brings up a foundational question about how we test new treatments.
- 3:40SPEAKER_00: Because we are going to be talking about phase three clinical trials today.
- 3:44SPEAKER_01: The heavyweight trials.
- 3:45SPEAKER_00: Let's say I invent a new therapy and I run a phase one or phase two trial.
- 3:49SPEAKER_00: I test it on 20 patients and the fistula is closed.
- 3:52SPEAKER_00: It looks like a miracle.
- 3:54SPEAKER_00: Why do regulators throw the brakes on and demand we run these massive, expensive phase three trials before we can offer it to patients who desperately need a lifeline?
- 4:03SPEAKER_01: Because a treatment that looks like an absolute miracle in 20 carefully selected people in one hospital can behave completely differently when you scaled up to 500 people across dozens of different countries.
- 4:15SPEAKER_00: Because the sample size is just too small to know for sure.
- 4:18SPEAKER_01: Early trials, you know, phase one and two, are really about answering basic questions.
- 4:23SPEAKER_01: Is this safe?
- 4:24SPEAKER_01: What is the right dose?
- 4:26SPEAKER_01: Does it show a signal that it might work?
- 4:28SPEAKER_01: But small groups are inherently noisy.
- 4:31SPEAKER_00: Noisy meaning you might just get lucky.
- 4:34SPEAKER_01: You might have accidentally selected patients whose immune systems were already primed to heal, or maybe one specific surgeon was just exceptionally skilled at the procedure.
- 4:43SPEAKER_01: Phase three is where the rubber meets the road.
- 4:45SPEAKER_00: The ultimate test.
- 4:46SPEAKER_01: It is a massive, highly controlled undertaking where you compare the new treatment directly against a placebo in a large, diverse population.
- 4:54SPEAKER_01: Regulators in Europe, Japan, and the U.S.
- 4:56SPEAKER_01: demand this because it flattens out that statistical noise.
- 4:59SPEAKER_00: It provides the heaviest, most undeniable weight of evidence that the benefit is actually coming from the drug itself and isn't just a fluke.
- 5:06unknown: Trevor Burrus, Jr.
- 5:06SPEAKER_01: That is the entire point of a phase three trial.
- 5:09SPEAKER_00: And that brings us to the drug that actually managed to clear this massive hurdle back in 2018.
- 5:14SPEAKER_00: It was called DarvidStrussel, marketed under the brand name Allofisol.
- 5:19SPEAKER_00: This is an injectable therapy that uses adipose-derived stem cells.
- 5:24SPEAKER_00: So researchers take cells extracted from a healthy donor's fat tissue, expand them in a laboratory into the millions, and then a surgeon injects this cell suspension directly into the tissue surrounding the fistula.
- 5:38SPEAKER_00: My brain immediately goes to a very specific visual here.
- 5:41SPEAKER_00: I picture these injected stem cells acting like microscopic construction workers.
- 5:46SPEAKER_01: Okay, I see where you're going with this.
- 5:47SPEAKER_00: Do they show up to the tunnel, start laying down new cellular bricks, and physically build new muscle and skin to plug the hole?
- 5:54SPEAKER_01: The construction worker analogy is probably the most common misconception in regenerative medicine.
- 5:59SPEAKER_01: The cells do not rebuild the tissue directly.
- 6:01SPEAKER_00: Wait, they don't turn into muscle.
- 6:03SPEAKER_01: They do not turn into the missing muscle or skin.
- 6:05SPEAKER_01: A much better way to visualize what is happening is to think of these cells as diplomats or peacekeepers being airdropped into a war zone.
- 6:13SPEAKER_00: Because the fistula is basically a localized war zone.
- 6:16SPEAKER_01: Remember, the tissue around a Crohn's fistula is wildly inflamed.
- 6:20SPEAKER_01: The patient's immune system is attacking its own tissue, creating a hostile environment where natural healing is impossible.
- 6:27SPEAKER_00: So the cells are dropping in to negotiate a ceasefire.
- 6:30SPEAKER_01: Exactly.
- 6:30SPEAKER_01: When you inject these adipose derived cells, they don't bring bricks, they bring biochemical signals.
- 6:36SPEAKER_01: They release specific proteins and molecules that command the local immune cells to calm down, they de-escalate the conflict.
- 6:43SPEAKER_00: So by shutting down that localized hostile inflammation, the treatment essentially buys the body time and space.
- 6:50SPEAKER_01: It changes the local environment so the patient's own tissue can finally get to work and repair the breach.
- 6:56SPEAKER_00: So they are telling the local immune system to stand down so the body can do its own construction work?
- 7:01SPEAKER_01: That is the mechanism.
- 7:03SPEAKER_01: And because they are modulating the immune response rather than acting as a like a quick-drying surgical glue, the results are not instant.
- 7:10SPEAKER_00: It's a gradual process.
- 7:11SPEAKER_01: The procedure itself is usually done outpatient under local or regional anesthesia.
- 7:16SPEAKER_01: But the actual closure of the fistula takes weeks, sometimes months, to fully materialize as the inflammation gradually subsides.
- 7:25SPEAKER_00: We also need to be incredibly precise about who this evidence actually applies to, because clinical trials are notorious for having strict velvet ropes.
- 7:33SPEAKER_01: Very strict inclusion criteria.
- 7:36SPEAKER_00: The participants in these trials were adults between 18 and 75, but the crucial detail is that they all had non-active or only mildly active luminal Crohn's disease, meaning their Crohn's was essentially quiet in the rest of their digestive tract.
- 7:50SPEAKER_01: They weren't experiencing massive systemic flare-ups.
- 7:53SPEAKER_00: The trial was laser focused on whether these cells could heal this specific anatomical tunnel, not whether they could cure the underlying autoimmune disease.
- 8:02SPEAKER_01: That's a vital distinction.
- 8:03SPEAKER_00: Also, every single person in this trial had already tried at least one conventional or biologic medication without lasting success.
- 8:10SPEAKER_00: So this isn't step one.
- 8:11SPEAKER_00: This is for patients whose fistulas have flat out refused to heal under standard medical care.
- 8:16SPEAKER_01: Understanding that patient profile makes the results of the initial trial, which was called Edemy Air CD, so much more striking.
- 8:23SPEAKER_01: This study was published in 2016.
- 8:25SPEAKER_01: They enrolled 212 adults across Europe and Israel.
- 8:29SPEAKER_00: A solid phase three size.
- 8:30SPEAKER_01: And at the 24-week mark, they looked at the data and found that 51.5% of the patients who received the Darvastrazol injection achieved combined remission.
- 8:41SPEAKER_01: Now compare that to the placebo group, where only 35.6% hit that mark.
- 8:46SPEAKER_00: Let's define combined remission because it sounds like a bureaucratic term, but biologically it is a very strict high bar.
- 8:52SPEAKER_01: Extremely strict.
- 8:53SPEAKER_00: For a patient to hit combined remission, every single treated external opening on their skin had to be completely closed.
- 9:00SPEAKER_00: No draining fluid, no open wounds.
- 9:02SPEAKER_00: But more importantly, the follow-up MRI scans had to confirm there were no hidden fluid collections larger than two centimeters hiding underneath the skin.
- 9:10SPEAKER_01: That hidden fluid metric is what makes or breaks fistula management.
- 9:13SPEAKER_00: Because the surface can look fine while it's a mess underneath.
- 9:20SPEAKER_01: But if the tunnel underneath is still inflamed and filling with fluid, it becomes a ticking time bomb.
- 9:25SPEAKER_01: It will eventually turn into an abscess, the pressure will build, and it will rupture.
- 9:31SPEAKER_00: So proving that the skin was closed and the underlying tract was free of significant fluid was a monumental achievement.
- 9:37SPEAKER_01: That roughly 16 percentage point gap between the stem cell group and the placebo group was statistically significant.
- 9:43SPEAKER_01: And that benefit held strong all the way through a 52-week follow-up.
- 9:48SPEAKER_00: And regulators loved it.
- 9:50SPEAKER_00: The European Commission looked at this phase three data and granted approval for allofecal in March 2018.
- 9:56SPEAKER_00: It became the very first allogenaic meaning donor-derived stem cell therapy ever approved in the European Union.
- 10:03SPEAKER_01: A huge milestone.
- 10:04SPEAKER_00: And it created a domino effect.
- 10:06SPEAKER_00: Approvals quickly rolled out in Japan, Israel, Switzerland, Serbia, and the United Kingdom.
- 10:10SPEAKER_00: It was heralded as this massive leap forward.
- 10:13SPEAKER_01: It was a massive leap forward at the time, but the regulatory agencies essentially said, we believe your 212-person study, but we want a larger follow-up trial to confirm the long-term safety and efficacy in a broader population.
- 10:25SPEAKER_00: So they needed a sequel to prove it wasn't a fluke.
- 10:28SPEAKER_01: That mandate led to the creation of Admire CD2.
- 10:31SPEAKER_00: Here's where it gets really interesting.
- 10:33SPEAKER_00: The blockbuster sequel.
- 10:35SPEAKER_00: They scaled it way up.
- 10:36SPEAKER_00: Admire CD2 enrolled 568 patients across Europe, Israel, and North America.
- 10:42SPEAKER_01: Nearly triple the size of the original study.
- 10:44SPEAKER_00: The drug is already on the market, surgeons are using it, patients are paying for it.
- 10:49SPEAKER_00: Everyone expects this massive trial to just rubber stamp the previous findings.
- 10:53SPEAKER_00: And then the 24-week results drop a decade later, and the gastroenterology world collectively gasps.
- 11:00SPEAKER_01: The results landed like a total bombshell.
- 11:02SPEAKER_01: In this much larger trial, the patients receiving the Darvod Strosal injection reach combined remission in 48.8% of cases.
- 11:09SPEAKER_00: Almost 50%.
- 11:10SPEAKER_00: Which sounds great on paper.
- 11:11SPEAKER_00: That is incredibly close to the 51.5% from the first trial.
- 11:15SPEAKER_01: It is.
- 11:16SPEAKER_01: But then the researchers looked at the placebo group.
- 11:19SPEAKER_01: The patients who received standard care and a sham injection reached combined remission in 46.3% of cases.
- 11:27SPEAKER_00: Wait, stop.
- 11:27SPEAKER_00: Let me make sure I'm wrapping my head around this.
- 11:29SPEAKER_00: 48.8% for the stem cells and 46.3% for the placebo.
- 11:34SPEAKER_01: The gap completely vanished.
- 11:36SPEAKER_00: That's less than a 3% difference.
- 11:38SPEAKER_01: And it wasn't just a blip at 24 weeks.
- 11:41SPEAKER_01: When they evaluated the patients at the 52-week mark, the numbers held steady at 41.0% for the treatment group and 39.7% for the placebo group.
- 11:51SPEAKER_00: So mathematically, it was a wash.
- 11:53SPEAKER_01: Statistically speaking, the stem cell therapy offered absolutely no meaningful clinical benefit over the placebo.
- 12:00SPEAKER_00: How is that physically possible?
- 12:01SPEAKER_00: I have to push back here because it defies logic.
- 12:03SPEAKER_00: We are talking about the exact same drug, the exact same adipose-derived cell product, treating the exact same condition.
- 12:10SPEAKER_01: Sounds impossible.
- 12:11SPEAKER_00: Did the stem cells suddenly give up and stop working a decade later?
- 12:15SPEAKER_00: Did the pharmaceutical company try to cut corners and change the expansion recipe in the lab?
- 12:19SPEAKER_00: You don't just have a miracle drug in 2016 that spontaneously stops functioning in 2026.
- 12:24SPEAKER_01: It is entirely counterintuitive until you look at the raw numbers of the placebo group over time.
- 12:30SPEAKER_01: The mechanism of the stem cells did not fail.
- 12:33SPEAKER_01: The manufacturer did not change the recipe.
- 12:36SPEAKER_01: As you pointed out, the Dorvet Stroh cell group performed almost exactly the same in both trials, hovering right around that 50% remission mark.
- 12:44SPEAKER_00: So the drug did exactly what it was supposed to do.
- 12:46SPEAKER_01: The aha moment for the entire medical community was realizing what happened to the control group.
- 12:51SPEAKER_01: In the original 2016 study, only about 35% of the placebo patients managed to heal.
- 12:57SPEAKER_01: A decade later, nearly 47% of them healed.
- 13:00SPEAKER_00: So the rising tide of standard medicine lifted all the boats in the trial.
- 13:04SPEAKER_01: Over those 10 years, the baseline of standard medical care underwent a quiet revolution.
- 13:09SPEAKER_01: The gastroenterology field introduced newer, far more effective biologic medications.
- 13:14SPEAKER_00: Like what?
- 13:14SPEAKER_00: What was changing?
- 13:15SPEAKER_01: We saw the rise of anti-integrant drugs and anti-IL-23 therapies.
- 13:20SPEAKER_01: These provided much better systemic control of the inflammation for patients who previously didn't respond to older medications.
- 13:27SPEAKER_00: So the systemic fire was being put out much more effectively.
- 13:30SPEAKER_01: On top of that, surgical techniques became much more refined.
- 13:34SPEAKER_01: Surgeons got better at placing and managing Sutton's.
- 13:37SPEAKER_01: Because every single patient in this trial, including the placebo group, was receiving this highly optimized, modernized standard of care, everyone's outcomes improved dramatically.
- 13:47SPEAKER_00: So the stem cells were almost certainly doing the exact same peacekeeper job they did in 2016, but their added value was completely swallowed up by the fact that the baseline medical care had simply gotten that much better.
- 14:00SPEAKER_01: The drug didn't fail, the control group caught up.
- 14:03SPEAKER_00: So the standard medicine essentially showed up with better tools and stole the stem cell's thunder.
- 14:08SPEAKER_00: That is a wild phenomenon.
- 14:09SPEAKER_00: So what does this all mean?
- 14:11SPEAKER_00: Because regulators don't care about the philosophical victory of standard medicine, they care about the statistical gap.
- 14:17SPEAKER_01: And without that gap, a drug can't justify its approval.
- 14:20SPEAKER_00: The fallout was incredibly swift.
- 14:22SPEAKER_00: Following the Admire CD2 results, Takeda, the manufacturer, formally requested the withdrawal of LFICL's market approval.
- 14:31SPEAKER_00: The European Medicines Agency officially withdrew it from the EU market in December 2024, stating that the clinical benefit just no longer justified its use.
- 14:40SPEAKER_01: And Japan followed suit.
- 14:42SPEAKER_00: Shortly after that, Japan announced it would discontinue sales in January 2026.
- 14:47SPEAKER_00: They effectively wiped the product off the map in every major market where it once held clearance.
- 15:02SPEAKER_00: It makes people wonder if all stem cell therapies are flawed.
- 15:05SPEAKER_01: It is vital for anyone listening to contextualize these findings based on geographic location and the specific biology of the cells being offered.
- 15:13SPEAKER_00: Let's bring this directly into the context of Cirona cell.
- 15:16SPEAKER_00: If you are a patient listening to this, maybe you are in Southeast Asia looking at clinics.
- 15:21SPEAKER_00: Cirona cell is based in Kuala Lumpur, and they treat both local patients in Malaysia and international patients flying in from around the world.
- 15:29SPEAKER_00: A critical distinction here is the raw material.
- 15:32SPEAKER_01: The cell source is everything.
- 15:34SPEAKER_00: Cyrona cell uses umbilical cord derived stem cells, specifically known in the literature as WJMSCs or Wharton's jelly mizenchemel stem cells.
- 15:44SPEAKER_01: The cell source is the most fundamental distinction you can make in this field.
- 15:47SPEAKER_01: WJMSEs are biologically entirely different from the adipose-derived product studied in the Ademeyer trials.
- 15:54SPEAKER_00: So you can't just lump them all together.
- 15:55SPEAKER_01: Taking cells from adult fat tissue versus taking them from Wharton's jelly in an umbilical cord yields cells with vastly different expansion potentials, different lifespans in culture, and distinct immunomodulatory profiles.
- 16:08SPEAKER_00: So it's like comparing a wrench to a screwdriver.
- 16:11SPEAKER_00: They're both tools, but they do different things.
- 16:13SPEAKER_01: Because they are biologically different tools, umbilical cord drive cells have their own totally separate ongoing track record of clinical evidence.
- 16:23SPEAKER_01: There are multiple active, independent academic trials right now investigating how umbilical cord MSCs influence severe inflammatory bowel conditions.
- 16:33SPEAKER_00: And that includes the ongoing research into their effects on ulcerative colitis.
- 16:37SPEAKER_01: You cannot paint all cell therapies with the same brush just because one specific adipose product lost its statistical edge.
- 16:48SPEAKER_00: Darwin Stressel was never actually reviewed by regulators or widely available in the Malaysian market in the first place.
- 16:54SPEAKER_01: It was essentially a non-factor there.
- 16:56SPEAKER_00: So its sudden withdrawal from the European and Japanese markets doesn't actually change the landscape of available options for a patient exploring therapies in Kuala Lumpur today.
- 17:05SPEAKER_00: It was never on the menu there to begin with.
- 17:07SPEAKER_01: Regardless of whether a patient is in Europe, America, or Southeast Asia, we have to maintain a strictly grounded, evidence-based perspective on what these therapies actually achieve.
- 17:17SPEAKER_00: No miracle cures.
- 17:18SPEAKER_01: It is crucial to state clearly: no stem cell treatment currently available cures Crohn's disease.
- 17:25SPEAKER_01: The foundational architecture of how doctors manage perineal fistulas remains completely unchanged by any of these trials.
- 17:32SPEAKER_00: And that foundation still relies heavily on combining advanced biologic medications with surgical intervention.
- 17:38SPEAKER_00: Specifically, the surgeon will often place a ceton.
- 17:41SPEAKER_01: Which is a very mechanical, practical tool.
- 17:44SPEAKER_00: A cetan is basically a soft, flexible piece of surgical thread looped through the fistula tract.
- 17:50SPEAKER_00: It acts as a physical drain.
- 17:52SPEAKER_00: It intentionally keeps the tract open so that fluid and infection cannot build up into a dangerous abscess under the skin.
- 17:58SPEAKER_01: It manages the local infection risk while the biologic medication works systemically to settle the underlying immune response.
- 18:04SPEAKER_00: When cell-based therapy is utilized by clinicians today, it is positioned to sit alongside that standard combination.
- 18:11SPEAKER_01: It functions as an adjunct therapy.
- 18:13SPEAKER_01: It is meant to provide an additional layer of local immunomodulation, calming the tissue directly at the site of the fistula.
- 18:19SPEAKER_00: It's an extra layer of support.
- 18:21SPEAKER_01: It is never designed to be a magical replacement for systemic biologics or necessary surgical drainage.
- 18:26SPEAKER_00: If you are a patient navigating this incredibly complex landscape and you are exploring cell-based options, the story of Darvidstra cell proves that you have to be rigorous.
- 18:37SPEAKER_00: You cannot just accept the word stem cells as a blanket cure-all.
- 18:41SPEAKER_00: You have to interrogate the science.
- 18:43SPEAKER_01: Any patient approaching a clinic should have a very specific checklist of questions.
- 18:47SPEAKER_01: Number one, ask them exactly which cell product or cell source they utilize.
- 18:52SPEAKER_01: Are they using adipose, bone marrow, or umbilical cord tissue?
- 18:55SPEAKER_00: Don't let them be vague about it.
- 18:57SPEAKER_01: Number two, ask to see the published, peer-reviewed clinical evidence for that exact cell source, not just generalized marketing brochures about the magic of stem cells.
- 19:06SPEAKER_00: Show me the data for what you're actually injecting.
- 19:08SPEAKER_01: Number three, inquire about their specific safety monitoring protocols during and after the infusion.
- 19:14SPEAKER_01: And finally, based on the specific MRI grading of your fistula, ask the clinician to define what a realistic, measurable outcome looks like for your individual case.
- 19:24SPEAKER_00: This entire saga leaves us with a lingering, almost paradoxical thought to mull over.
- 19:29SPEAKER_00: When you look really closely at the story of Darwidstrosol, it is actually a strange kind of good news.
- 19:36SPEAKER_01: For the patients, absolutely.
- 19:37SPEAKER_00: The drug didn't fail the patients.
- 19:39SPEAKER_00: Standard medicine just improved so rapidly, so efficiently, that it caught up to the breakthrough.
- 19:44SPEAKER_00: But this raises a fascinating, almost daunting question for the future of medical research.
- 19:49SPEAKER_00: If standard medical care, surgical techniques, and biologic therapies keep improving at this rapid exponential pace, how will any new breakthrough treatment in the future ever manage to prove it is significantly better than a placebo?
- 20:02SPEAKER_01: The hurdle just keeps getting higher.
- 20:04SPEAKER_00: Simply because we keep getting better at treating the baseline.
- 20:07SPEAKER_00: It's an incredible problem to have, but it completely changes the game for medical innovation.
- 20:12SPEAKER_00: If you are considering whether a stem cell evaluation makes sense for your specific case and you want to discuss your fistula history and current treatment plan with a medical professional, you can message the Cyrona Cell team on WhatsApp for a free medical review.
- 20:26SPEAKER_00: We will see you on the next deep dive.